Benzinga | Nov 2, 2021 05:58PM EDT

Agile Therapeutics Q3 EPS $(0.18) Beats $(0.19) Estimate, Sales $1.29M Miss $1.46M Estimate

Agile Therapeutics (NASDAQ:AGRX) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.19) by 5.26 percent. This is unchanged from the same period last year. The company reported quarterly sales of $1.29 million which missed the analyst consensus estimate of $1.46 million by 11.85 percent.